{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0","value":"0.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"Will be measured by next-generation sequencing. The percent change in mutant allele burden will be analyzed descriptively. Values will be summarized with means and standard deviations.","dispersionType":"Standard Deviation","groups":[{"description":"Patients receive trametinib PO QD on days 1-28 of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo a bone marrow aspiration or biopsy at baseline, on day 28 of cycles 1 and 2, at all subsequent odd numbered cycles, and at end of treatment.","id":"OG000","title":"Treatment (Trametinib)"}],"paramType":"MEAN","populationDescription":"All patients who met the evaluable for response criteria outlined in section 9.4 of the ADVL1521 protocol.","reportingStatus":"POSTED","timeFrame":"Up to cycle 12 (1 cycle = 28 days)","title":"Mutant Allele Burden","type":"SECONDARY","unitOfMeasure":"Percent Change In Mutant Allele Burden"}